

Ethan Levin

EthanLevin@gmail.com

(716) 812-9434 m

TRAINING

Micrographic Surgery and Dermatologic Oncology Fellowship, Washington University	2018 to Present
Dermatology Residency, University of California, San Francisco (UCSF)	2015-2018
Psoriasis Clinical Research Fellowship, Department of Dermatology, UCSF	2012-2015
Internal Medicine Internship, Mt. Sinai Beth Israel Hospital – New York	2011-12

EDUCATION

UCSF, Department of Epidemiology and Biostatistics – Master’s Program in Clinical Research	2015
Washington University School of Medicine (WUSM) – M.D.	2007-11
Cornell University – B.S. in Biological Sciences, <i>summa cum laude</i>	2003-7
Institute for International Studies, Spain	2006

CERTIFICATION AND LICENSURE

Diplomate, American Board of Dermatology	2018
Missouri Medical License 2018009601	2018 to Present
California Medical License A122015	2012 to Present

HONORS AND AWARDS

National Psoriasis Foundation Medical Dermatology Fellowship Award (\$40,000)	2014
Mentoring Program for Medical Dermatology Fellows	2013
Selected as one of fifteen fellows	
WUSM, Honors in eight of eleven clinical courses	2009-10
WUSM, Honors in sixteen of seventeen preclinical courses	2008-9
Cornell University Hughes Scholar	2006
Selected as one of twenty Howard Hughes Medical Institute Undergraduate Research Scholars	
Cornell University, graduating GPA: 4.06	
Hauptman-Woodward Research Apprentice Program	2004
Selected as one of five national research scholars	

LICENSING EXAMS

USMLE Step 1: 253 Step 2: 257 Step 3: 239

LEADERSHIP ROLES/ PROFESSIONAL ACTIVITIES

UCSF Grand Rounds Chief	2017-2018
Organize weekly Grand Rounds patient presentations with three of my co-residents	
San Francisco Dermatological Society, Board Member	2016-2018
Organized case presentations for annual 2016 meeting attended by ~100 community dermatologists	
Resident Journal Club President	2015-2016
Selected articles and led monthly resident journal club	
National Psoriasis Foundation (NPF), Northern California Division	2012-2015
i. One of four physicians selected by the NPF to lobby congress for improved access to patient care and for psoriasis research funding in 2013, 2014 and 2015, Washington, DC	
ii. UCSF Team Captain for the Walk to Cure Psoriasis. Raised \$10,000 for NPF.	
First place in medical center fundraising. http://vimeo.com/73996482	
Representative, Beth Israel Internal Medicine House Staff Council	2011-12
Elected by peers as one of fifteen members.	
Founder, St. Louis Sprint for Skin Cancer	2010
Organized inaugural five-kilometer, one hundred and fifty participant race to increase skin cancer awareness. Raised \$8000 for the Siteman Cancer Center at WUSM.	
President, Wine Society	2008-9
Coordinated and ran biannual wine tastings for eighty students and faculty	
Charles Maryland LLC	2008
Founded company to invest in restoration of historic property in St. Louis	
Captain and Treasurer, Cornell Junior Varsity Soccer	2003-7
Managed team budget, organized \$2000 in fundraising, led practices and coordinated tournaments	

RESEARCH EXPERIENCE

University of California, San Francisco	2017
Department of Dermatologic Surgery	
Mentor: Sarah Arron, MD, PhD	
Project: Determine whether post-operative prophylactic antibiotics reduce the rate of post-operative wound infection using data from the American College of Mohs Surgery pilot registry	
University of California, San Francisco	January 2017 to Present
Department of Dermatology	
Mentor: Phil LeBoit, MD	
Project: Characterize the histopathology, genetics and natural history of keratoacanthoma arising within lichen planus and to identify the optimal surgical and medical management strategies of these lesions.	
Psoriasis Clinical Research Fellow, UCSF Department of Dermatology	2012-2015

Mentor: John Koo, MD

- Sub-investigator and study coordinator for 18 clinical trials
- Designed and implemented protocols (for investigator initiated studies), prepared IRB submissions, reported adverse-events, created source documents, recruited patients, performed study assessments, and received, stored, dispensed, and administered investigational product
- Therapies studied include anti-IL17A antibodies (secukinumab, brodalumab, ixekizumab), anti-IL23 antibodies (tildrakizumab, guselkumab), ustekinumab, etanercept, and adalimumab; oral janus kinase inhibitor (tofacitinib); excimer laser, clobetasol spray, vectical ointment
- Editor of *Mild-to-Moderate Psoriasis* 3rd edition and *Moderate-to-Severe Psoriasis* 4th edition

Washington University in St. Louis School of Medicine

2010

Department of Surgical Pathology

Mentor: John Pfeifer, MD, PhD

Project: Participated in the study of V600E BRAF mutation in thyroid carcinoma using molecular techniques including DNA purification, PCR, qPCR, FISH, and DNA subcloning

Washington University in St. Louis School of Medicine

2008

Department of Immunology

Mentor: Paul Allen, PhD

Project: Studied T-cell receptor downregulation by *salmonella* using techniques including T-cell purification of wild-type and TLR knockout mice and flow cytometry

Cornell University

2005-7

Department of Neurobiology and Behavior

Mentor: Ronald Hoy, PhD

Project: Examined the acoustic behavior of the parasitoid fly *ormia* using MatLab to control sound stimuli and high-speed video to record data

Hauptman-Woodward Medical Research Institute, Buffalo, NY

2004

Mentor: Andrew Gulick, PhD

Project: Worked to improve crystallization of enterobactin, a nonribosomal peptide synthetase, through reductive methylation of lysine residues

CLINICAL TRIALS EXPERIENCE

Principal Investigator

Single-site, Investigator Initiated Studies

1. Excimer Laser Phototherapy Outcomes in the Treatment Of Psoriasis: A randomized clinical trial to determine whether a novel plaque-based dosimetry strategy can improve the speed of response to treatment in patients with plaque psoriasis

Co-investigator

Single-site, Investigator Initiated Studies

2. Characterization of the response to secukinumab in plaque psoriasis using novel immunologic and genetic profiling.
3. Open-label study to test the efficacy and safety of excimer laser combined with clobetasol spray and calcitriol ointment for the treatment of generalized plaque psoriasis
4. Predicting treatment response to ustekinumab using lymphocyte immunophenotyping in patients with moderate-to-severe psoriasis
5. Effect of excimer laser on lymphocyte functional differentiation in psoriatic skin
6. Open-Label study to assess psychosocial and occupational dimensions in patients with moderate-to-severe psoriasis before and after treatment with ustekinumab

Multi-center Clinical Trials

7. A Phase 3 study evaluating the efficacy and safety of guselkumab for the treatment of subjects with moderate to severe plaque-type psoriasis
8. A Phase 3b study to evaluate “subject-tailored” maintenance dosing of ustekinumab in subjects with moderate-to-severe plaque psoriasis
9. A phase 3 study to evaluate the safety and efficacy of subcutaneous tildrakizumab followed by an optional long-term safety study in subjects with moderate-to-severe plaque psoriasis
10. A Phase 3 study assessing long-term safety and efficacy of subcutaneous secukinumab in moderate-to-severe plaque psoriasis
11. A Phase 3 study to evaluate the efficacy and safety of brodalumab in subjects with moderate-to-severe plaque psoriasis
12. A Phase 3 study to evaluate the efficacy and safety of brodalumab compared with placebo and ustekinumab in subjects with moderate to severe plaque psoriasis
13. A Phase 3, open-label extension study assessing long-term safety and tolerability of oral tofacitinib in subjects with moderate-to-severe plaque psoriasis
14. A Phase 3 study assessing the safety and efficacy of oral tofacitinib in subjects with moderate-to-severe plaque psoriasis
15. A 10-year, observational registry of adult patients with chronic plaque psoriasis treated with adalimumab

INVESTIGATOR INITIATED RESEARCH GRANTS

1. **Levin EC**, Rosenblum M, Liao W. Characterization of the response to secukinumab in plaque psoriasis using novel immunologic and genetic profiling, 2016 - Present
2. **Levin EC**, Koo J. Excimer Laser Phototherapy Outcomes in the Treatment Of Psoriasis: A randomized clinical trial to determine whether a novel plaque-based dosimetry strategy can improve the speed of response to treatment in patients with plaque psoriasis, 2015 – Present

PATENTS

Ethan Levin, John Koo, Maya Debbaneh. 2015. Plaque Targeted Sub-Blistering Dosimetry. US2014/058957, filed March 10, 2014, and issued September 4, 2015.

PUBLICATIONS/ PRESENTATIONS

Textbooks

1. *Mild-to-moderate psoriasis*. 3rd edition. Koo J, **Levin EC**, Leon A, Wu JJ, Lebwohl M, eds. Boca Raton: CRC Press; 2014.
2. *Moderate-to-severe psoriasis*. 4th edition. Koo J, **Levin EC**, Leon A, Wu JJ, Gottlieb A, eds. Boca Raton: CRC Press; 2014.

Guest Editor

3. *Psychodermatology*. Koo J, Leon A, **Levin EC**, eds. Seminars in Cutaneous Medicine and Surgery. 2013; 32(2): 63-129.

Original Articles

4. Beroukhim K, Wang JZ, Schulman JM, **Levin E**, Liao W, Danesh M. Examination of tar-induced verrucous growths reveals absence of human papillomavirus. *American Journal of Dermatopathology*. 2018; In press.
5. Sekhon S, Jeon C, Nakamura M, Yan D, Afifi L, Bhutani T, **Levin EC**. Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis. *Psoriasis: Targets and Therapy*. 2017;7:65-72. PMID: 29387609
6. **Levin EC**, Chow C, Makhzoumi Z, Jin C, Shiboski SC, Arron ST. Association of post-operative antibiotics with surgical site infection in Mohs micrographic surgery. *Dermatologic Surgery*. 2018 Epub Ahead of Print. PMID: 30148738
7. Sorenson E, **Levin EC**, Liao W. The efficacy of biologic therapy for the management of palmoplantar psoriasis and palmoplantar pustulosis: a systematic review. *Dermatology & Therapy*. 2017;7(4):425-446. PMID: 29143230
8. Armstrong AW, Cather JC, Paul CF, Edson-Heredia E, Zhu B, Hollister K, Koo J, **Levin E**, Bleakman AP. Association of Touch Avoidance with Disease Severity and Quality of Life in Psoriasis Patients. *Journal of Psoriasis and Psoriatic Arthritis*. 2017; 2(3)
9. **Levin EC**, Sofen B, Yu S. A simple technique to optimize second intention healing of nasal alar and tip repairs. *Dermatologic Surgery*. 2017 Epub Ahead of Print. PMID: 28945619
10. Chaudhari S, Leon A, **Levin E**, Neuhaus I, Liao W. Multiple Keratoacanthomas and Squamous Cell Carcinomas in a Patient Receiving Pembrolizumab. *Journal of Drugs and Dermatology*. 2017;16(5):513-515. PMID: 28628690
11. Malakouti M, Brown GE, Leon A, Naegeli AN, Edson-Heredia E, **Levin E**, Koo J. The dermatologic intimacy scale: quantitatively measuring the impact of skin disease on intimacy. *Journal of Dermatological Treatment*. 2017 Jun;28(4):347-352. PMID: 27764972

12. Abrouk M, **Levin E**, Brodsky M, Gandy JR, Nakamura M, Zhu TH, Farahnik B, Koo J, Bhutani T. Excimer laser for the treatment of psoriasis: safety, efficacy, and patient acceptability. *Psoriasis: Targets and Therapy*. 2016 Dec;6:165-173. PMID: 29387603
13. Beroukhim K, Danesh M, Nguyen C, Farahnik B, **Levin E**, Leon A, Koo J. A prospective, interventional assessment of the impact of ustekinumab treatment on psoriasis-related work productivity and activity impairment. *Journal of Dermatological Treatment*. 2016 Nov;27(6):552-555. PMID: 27052387
14. **Levin E**, Nguyen CM, Danesh MJ, Beroukhim K, Leon A, Koo J. An open label pilot study of supraerythemogenic excimer laser in combination with clobetasol spray and calcitriol ointment for the treatment of generalized plaque psoriasis. *Journal of Dermatological Treatment*. 2016;27(3)210-3. PMID: 26329774
15. Beroukhim K, Danesh MJ, Nguyen C, Austin A, Koo J, **Levin E**. Anti-IL-23 Phase II Data for Psoriasis: A Review. *Journal of Drugs and Dermatology*. 2015 Oct;14(10):1093-6. PMID: 26461819
16. Lu D, **Levin EC**, Dehner LP, Lind AC. Proliferative activity in melanocytic nevi from patients grouped by age with clinical follow-up. *Journal of Cutaneous Pathology*. 2015; In Press. PMID: 26268063
17. Sorenson E*, **Levin E***, Koo J, Berger TG. Successful use of a modified Goeckerman regimen in the treatment of generalized prurigo nodularis. *Journal of the American Academy of Dermatology*. 2015 Jan;72(1):e40-2. PMID: 25497953 [*co-first authors]
18. Sorenson E, McAndrew R, Patel V, Logan AC, Koo J, **Levin E**. Narrowband UV-B Phototherapy for Steroid-Refractory Sclerotic Chronic Cutaneous Graft-vs-Host Disease. *JAMA Dermatology*. 2015 Jun;151(6):635-7. PMID: 25806783
19. Danesh MJ, Butler DC, Beroukhim K, Nguyen C, Tartar D, **Levin E**, Koo J. A cross-sectional survey study to evaluate phototherapy training in dermatology residency. *Photodermatology Photoimmunology and Photomedicine*. 2015 Sep;31(5):269-70. PMID: 26018552
20. Beroukhim K, Farahnik B, Danesh M, Nguyen C, Koo J, **Levin E**. Clinical Severity Measures for Psoriasis: A Case for the PASI. *Journal of Psoriasis and Psoriatic Arthritis*. 2016
21. McAndrew R, **Levin E**, Koo J. Emerging Oral Immunomodulators for the Treatment of Psoriasis: A Review of Phase III Clinical Trials for Apremilast and Tofacitinib. *Journal of Drugs and Dermatology*. 2015 Aug;14(8):786-92. PMID: 26267722
22. Danesh MJ, Beroukhim K, Nguyen C, **Levin E**, Koo J. Apremilast and adalimumab: a novel combination therapy for recalcitrant psoriasis. *Dermatology Online Journal*. 2015 Jun;21(6) PMID: 26158370
23. Leon A, Beroukhim K, Danesh M, Nguyen C, Lee K, Farahnik B, Zhu T, Abrouk M, Wang E, Malakouti M, Brown G, **Levin E**, Koo J. The Correlation between the Dermatology Life

- Quality Index and the Psoriasis Area Severity Index. *Journal of Psoriasis and Psoriatic Arthritis*. 2015;1(1)
24. Malakouti M, Brown GE, Wang E, Koo J, **Levin EC**. The role of IL-17 in Psoriasis. *Journal of Dermatological Treatment*. 2015 Feb;26(1):41-4. PMID: 24552504
 25. Brown G, Malakouti M, Wang E, Koo J, **Levin E**. Anti-IL-17 phase II data for psoriasis: A review. *Journal of Dermatological Treatment*. 2015 Feb;26(1): 32-36. PMID: 24552447
 26. Debbaneh M*, **Levin E***, Sanchez Rodriguez R, Leon A, Koo J, Rosenblum MD. Plaque-based sub-blistering dosimetry: Reaching PASI-75 after two treatments with 308 nm excimer laser in a generalized psoriasis patient. *Journal of Dermatological Treatment*. 2015 Feb;26(1):45-8. PMID: 24552548 [*co-first authors]
 27. **Levin EC**, Debbaneh M, Malakouti M, Brown G, Wang E, Gupta R, Butler D, Huynh M, Leon A, Koo J. Supraerythemogenic Excimer Laser in Combination with Clobetasol Spray and Calcitriol Ointment for the Treatment of Generalized Plaque Psoriasis: Interim Results of an Open Label Pilot Study. *Journal of Dermatological Treatment*. 2015 Feb;26(1):16-8. PMID: 24547791
 28. Rodriguez RS, Pauli M, Neuhaus I, Yu S, Arron ST, Harris HW, Yang SH, Anthony BA, Sverdrup FM, Krow-Lucal E, MacKenzie TC, Johnson DS, Hsu AR, Lohr A, Koo J, Liao W, Gupta R, Debbaneh MG, Butler D, Huynh M, **Levin EC**, Leon A, Hoffman WY, McGrath MH, Alvarado MD, Ludwig CH, Truong H, Maurano MM, Gratz IK, Abbas AK, Rosenblum MD. Memory Regulatory T cells are a Unique Population Resident in Human Skin. *Journal of Clinical Investigation*. 2014 Mar;124(3): 1027-1036. PMID: 24509084
 29. Malakouti M, Brown GE, Sorenson E, Leon A, Koo J, **Levin EC**. Successful use of the excimer laser for generalized psoriasis in an ustekinumab non-responder. *Dermatology Online Journal*. 2014 Dec;21(3). PMID: 257808961
 30. **Levin EC**, Debbaneh M, Koo J, Liao W. Biologic Therapy in Erythrodermic and Pustular Psoriasis. *Journal of Drugs in Dermatology*. 2014 Mar;13(3):342-54. PMID: 24595581
 31. **Levin EC**, Gupta R, Brown G, Malakouti M, Koo J. Biologic Fatigue in Psoriasis. *Journal of Dermatological Treatment*. 2014 Feb; 25(1):78-82. PMID: 23875537
 32. **Levin EC**, Gupta R, Chiang C, Butler D, Koo J. Topical Steroid Risk Analysis: Differentiating between physiologic versus pathologic adrenal suppression. *Journal of Dermatological Treatment*. 2014 Dec;25(6):501-6. PMID: 24171390
 33. **Levin EC**, Gieler U. Delusions of Parasitosis. *Seminars in Cutaneous Medicine and Surgery*. 2013 Jun; 32(2): 73-77. PMID: 24049963
 34. **Levin EC**, Gupta R, Shinkai K. Duration of Remission of Topical Psoriasis Therapies. *Psoriasis Forum*. 2013; 19(1): 22-33.
 35. Chaudhari S, Leon A, **Levin E**, Koo J. Systematic Review of Phototherapy in Pruritic Disorders. *Journal of the American Osteopathic College of Dermatology*. 2014; 31: 42-50.

36. Chaudhari S, Leon A, **Levin E**, Chaudhari O, Koo J. Pathogenesis of Pruritic Disorders and Mechanisms of Phototherapy. *Journal of the American Osteopathic College of Dermatology*. 2014; 32: 29-33.
37. Gupta R, Wu JJ, **Levin EC**, Koo J, Liao W. Possible Drug-Drug Interaction Between Adalimumab and Duloxetine and/or Pregabalin in a Psoriasis Patient. *Journal of Drugs in Dermatology*. 2013 Oct; 12(10):1089. PMID: 24085041
38. Koo J, Leon A, **Levin EC**. Psychodermatology. *Seminars in Cutaneous Medicine and Surgery*. 2013 Jun; 32(2): 63. PMID: 24049960
39. Koo J, Leon A, **Levin EC**. Psychodermatology: An Overview. *Seminars in Cutaneous Medicine and Surgery*. 2013 Jun; 32(2): 64-67. PMID: 24049961
40. Gupta R, **Levin EC**, Wu JJ, Koo J, Liao W. An Update on Drug-Drug Interactions with Biologics for the Treatment of Moderate to Severe Psoriasis. *Journal of Dermatologic Treatment*. 2014 Feb;25(1):87-9. PMID: 23855593
41. Gupta R, Debbaneh M, Butler D, Huynh M, **Levin EC**, Leon A, Koo J, Liao, W. The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis. *Journal of Visualized Experiments*. 2013 Jul;(77). (<http://www.jove.com/video/50509/the-goeckerman-regimen-for-treatment-moderate-to-severe>) PMID: 23892536
42. Gupta R, **Levin EC**, Nguyen T, Shinkai K. Merits of Maintenance Phototherapy for Psoriasis. *Psoriasis Forum*. 2013; 19(1): 34-40.
43. Lu Y, Vogel S, Chen H, Leon A, **Levin EC**, Nguyen T, Debbaneh M, Wong J, Gupta R, Huyhn M, Butler D, Cordoro K, Liao W. The Role of 39 Psoriasis Risk Variants on Age of Psoriasis Onset. *ISRN Dermatology*. 2013 Sep;203941. PMID: 24175098
44. Buter D, Huynh M, Gupta R, **Levin EC**, Leon A, Koo J. Psoriasis: Impact on Quality of Life. *Psoriasis Forum*. 2013; 19(1): 16-20.
45. Huynh M, Debbaneh M, Butler D, Gupta R, **Levin EC**, Leon A, Koo J. Common Phototherapy Mistakes and How to Avoid Them. *Journal of the American Osteopathic College of Dermatology*. 2013; 28: 13-14.
46. Huynh M, **Levin EC**, Koo J. Scalp Psoriasis treated with Excimer Laser, Clobetasol Propionate Spray and Calcitriol Ointment. *Journal of the American Osteopathic College of Dermatology*. 2013; 27: 48-49.
47. Butler DC, Gupta R, **Levin EC**, Huynh M, Leon A, Koo J. Psoriasis and Quality of Life. *Hong Kong Journal of Dermatology and Venereology*. 2013; 21(2): 64-68.
48. Huynh M, Gupta R, **Levin EC**, Butler D, Leon A, Koo J. Stress on Psoriasis. *Psoriasis Forum*. 2012; 18(4):179-184.
49. Jung J, **Levin EC**, Mann C. Lymphomatoid drug reaction after treatment with ustekinumab. *Archives of Dermatology*. 2011 Aug;147(8): 992-3. PMID: 21844471
50. **Levin EC**, Joshi R, Brasington R. Acute presentation of tophaceous myelopathy. *Journal of Rheumatology*. 2011 Jul; 38(7): 1525-26. PMID: 21724731

51. Rosen MJ, **Levin EC**, Hoy RR. The cost of assuming the life history of a host: acoustic startle in the parasitoid fly *Ormia ochracea*. *Journal of Experimental Biology*. 2009 Nov; 212(24): 4056-4064. PMID: 19946084

Textbook Chapters

52. **Levin EC**, Koo J. Fixed Dose Corticosteroid/Calcipotriene Combination Therapy. In: Mild-to-moderate psoriasis. Koo J, Levin EC, Leon A, Wu JJ, Lebwohl M, eds. CRC Press, Boca Raton, 3rd ed, 2014, pp 49-62.
53. **Levin EC**, Ellis C. Cyclosporine. In: Moderate-to-severe psoriasis. Koo J, Levin EC, Leon A, Wu JJ, Gottlieb A, eds. CRC Press, Boca Raton, 4th ed, 2014, pp 169-190.
54. **Levin EC**, Koo J, Gottlieb A. Infliximab. In: Moderate-to-severe psoriasis. Koo J, Levin EC, Leon A, Wu JJ, Gottlieb A, eds. CRC Press, Boca Raton, 4th ed, 2014, pp 231-247.
55. **Levin EC**, Leon A, Butler D, Koo J. IL-17 and Other New Agents. In: Moderate-to-severe psoriasis. Koo J, Levin EC, Leon A, Wu JJ, Gottlieb A, eds. CRC Press, Boca Raton, 4th ed, 2014, pp 261-275.
56. **Levin EC**, Sako E, Famenini S, Wu JJ. Erythrodermic and Pustular Psoriasis. In: Moderate-to-severe psoriasis. Koo J, Levin EC, Leon A, Wu JJ, Gottlieb A, eds. CRC Press, Boca Raton, 4th ed, 2014, 277-288.
57. **Levin EC**, Koo J. Biologic Fatigue. In: Moderate-to-severe psoriasis. Koo J, Levin EC, Leon A, Wu JJ, Gottlieb A, eds. CRC Press, Boca Raton, 4th ed, 2014, 249-260.
58. Butler DC, Kamangar F, **Levin EC**, Koo J, Chang ALS. Psoriasis Therapy is Special Patient Populations. In: Moderate-to-severe psoriasis. Koo J, Levin EC, Leon A, Wu JJ, Gottlieb A, eds. CRC Press, Boca Raton, 4th ed, 2014, pp 335-348.
59. Butler DC, Bhutani T, **Levin EC**, Wang E, Koo J. Systemic Retinoids. In: Moderate-to-severe psoriasis. Koo J, Levin EC, Leon A, Wu JJ, Gottlieb A, eds. CRC Press, Boca Raton, 4th ed, 2014, pp 139-150.
60. Huynh M, Debbaneh M, **Levin EC**, Koo J. The Art and Practice of UVB Phototherapy and Laser for the Treatment of Moderate-to-Severe Psoriasis. In: Moderate-to-severe psoriasis. Koo J, Levin EC, Leon A, Wu JJ, Gottlieb A, eds. CRC Press, Boca Raton, 4th ed, 2014, pp 67-97.
61. Fisk W, **Levin EC**, Hong J, Koo J. Dietary Therapy for Psoriasis: Protein Restrictive Diets. In: Mild-to-moderate psoriasis. Koo J, Levin EC, Leon A, Wu JJ, Lebwohl M, eds. CRC Press, Boca Raton, 3rd ed, 2014, pp 201-208.
62. Fisk W, **Levin EC**, Hong J, Koo J. Biologic Therapy and the Risk of Systemic Immunosuppression. In: Moderate-to-severe psoriasis. Koo J, Levin EC, Leon A, Wu JJ, Gottlieb A, eds. CRC Press, Boca Raton, 4th ed, 2014, pp 373-377.

Nonprint Materials

63. **Levin EC**, Bogucki B, Nunley KS. Lower Extremity Rash and Pancytopenia in HIV patient.

Oral Presentations

1. **Levin EC.** “Excimer laser for Psoriasis and Beyond: Developing novel dosimetry strategies to optimize patient response,” Resident Expert Talk, UCSF Department of Dermatology Grand Rounds. February 2018. San Francisco, CA.
2. **Levin EC.** “Association of Antibiotics with Wound Infection in Mohs Micrographic Surgery,” Mohs Micrographic Surgery Oral Abstract Presentations, American Society for Dermatologic Surgery Annual Meeting. October 2017. Chicago, IL.
3. **Levin EC.** “A Simple Technique to Optimize Second-intention Healing of Nasal Alar and Tip Defects,” Rapid Pearls Session, American College of Mohs Surgery Annual Meeting. April 2017. San Francisco, CA.
4. **Levin EC.** “Excimer Laser for Psoriasis: Plaque Based Dosimetry Can Increase Rapidity of Response,” Phototherapy Forum, American Academy of Dermatology Annual Meeting. March 2017. Orlando, FL.
5. **Levin EC.** “Plaque Based Sub-Blistering Dosimetry with Excimer Laser: Clearing Psoriasis with as few as two Phototherapy Sessions,” Phototherapy Forum, American Academy of Dermatology Annual Meeting. March 2016. Washington, DC.
6. **Levin EC.** “Acquired Bullous Acrodermatitis Enteropathica in a Patient on Total Parenteral Nutrition,” University of California San Francisco Annual Great Cases Forum. August 2016. San Francisco, CA.
7. **Levin EC.** “Excimer laser in the treatment of psoriasis,” Phototherapy Forum, American Academy of Dermatology Annual Meeting. March 2015. San Francisco, CA.
8. **Levin EC.** “The Emotional Impact of Psoriasis and Psoriatic Arthritis,” More Than Skin Deep National Psoriasis Foundation Conference. February 2014. San Francisco, California.
9. **Levin EC.** “Phototherapy in Review and ‘What’s New?’,” Dermatology Nurses Association Annual Update. November 2013. San Francisco, California.
10. **Levin EC, Koo J.** “Update on Psoriasis Therapy,” Dermacon 2013. Ahmedabad, India.
11. **Levin EC, Koo J.** “Innovative Treatment for Generalized Psoriasis: 308nm Excimer Laser, Clobetasol Spray, and Calcitriol Ointment,” Paving the Way for the Future Medical Dermatology Leaders in Psoriasis and Psoriatic Arthritis: 1st Annual Dermatology Fellows Program 2013. Cleveland, OH.
12. **Levin EC, Koo J.** “Relative Merits of Various Antipsychotic Medications Used to Treat Delusions of Parasitosis,” 23rd Annual Meeting of the Association of Psychoneurocutaneous Medicine of North America 2013. Miami, Florida.
13. **Levin EC, Debbaneh M, Liao W, Koo J.** “The Science of Psoriasis,” National Psoriasis Foundation Webcast. August 2013.

14. **Levin EC**, Lind A. “Seventy-four-year-old white man with persistent red, scaly patch on cheek,” Department of Surgical Pathology Conference 2010. Washington University School of Medicine. St. Louis, MO.
15. **Levin EC**, Allen P. “Investigating the T-cell response to Salmonella Typhimurium,” Department of Immunology Conference 2008. Washington University School of Medicine. St. Louis, MO.
16. **Levin EC**, Rosen MJ, Hoy RR. “Convergent Evolution in Parasitoid and Host: Acoustic Startle Response and Categorical Perception,” Hughes Scholars Conference 2006. Ithaca, NY.
17. **Levin EC**, Rosen MJ, Hoy RR. “Phonotactic Behavior of *Ormia ochracea*,” Hoy Lab Conference 2005. Ithaca, NY.
18. **Levin EC**, Gulick A. “Reductive Methylation of EntB Lysine Residues,” Hauptman-Woodward Research Apprentice Program Conference 2004. Buffalo, NY.

Selected Poster Presentations/Abstracts

1. **Levin EC**, Kinnebrew M, Mathes E. “Congenital Lymphedema,” San Francisco Dermatological Society Annual Meeting 2016. San Francisco, CA.
2. Bleakman A, Armstrong A, Edson-Heredia E, **Levin E**, Zhu B, Robertson A, Hollister K, Koo J. “Association of Touch Avoidance with Disease Severity and Quality of Life in Psoriasis Patients,” 23rd World Congress of Dermatology 2015. Vancouver, Canada.
3. **Levin EC**, Brown G, Malakouti M, Leon A, Naegeli AN, Edson-Heredia E, Koo J. “Development and preliminary validation of a questionnaire to assess social and personal intimacy in skin disease: the dermatologic intimacy scale,” 23rd EADV Congress 2014. Amsterdam, Netherlands.
4. Debbaneh M, **Levin EC**, Gupta R, Huynh M, Butler D, Leon A, Koo J. Innovate treatment option for moderate-to-severe generalized psoriasis using 308-nm excimer laser, clobetasol spray and calcitriol ointment. American Academy of Dermatology 2014 Annual Meeting. Denver, CO.
5. Gupta R, **Levin EC**, Butler D, Leon A, Koo J. A Single-Center, Open-Label Study to Assess Change in Psychosocial and Occupational Dimensions with Ustekinumab Treatment of Moderate-to-Severe Psoriasis Evaluated with the Psychological General Well Being (PGWB), Work Productivity and Activity Impairment (WPAI), Psoriasis Quality of Life-12 Items (PQOL-12), and Dermatology Life Quality Index (DLQI). American Academy of Dermatology 2014 Annual Meeting. Denver, CO.
6. **Levin EC**, Braudis K, Liao W, Connolly K. “Prodromal Bullous Pemphigoid,” Pacific Dermatologic Association: Clinicopathologic Conference 2013. San Francisco, CA.
7. **Levin EC**, Butler D, Gupta R, Bhutani T, Koo J, “Innovative Treatment for Generalized Psoriasis: 308nm Excimer Laser, Clobetasol Spray, and Calcitriol Ointment,” Dermacon 2013. Ahmedabad, India.

8. **Levin EC**, Rosen MJ, Hoy RR. “Characterizing an acoustic startle response in the parasitoid fly *Ormia ochracea*: convergent evolution between parasite and host,” 11th International Conference on Invertebrate Sound and Vibration, University of Toronto 2006. Toronto, Canada.
9. **Levin EC**, Rosen MJ, Hoy RR. “An Acoustic Startle Response in a Parasitoid Fly,” Hughes Scholars Poster Session, Cornell University 2006. Ithaca, NY.